Fig. 2

tRF AS-tDR-007333 is up-regulated in NSCLC and associated with worse prognosis in patients with NSCLC. A AS-tDR-007333 expression level in pre-operation plasma was higher than that in post-operation plasma samples. B Expression levels of plasma AS-tDR-007333 in patients with NSCLC (n = 29) were significantly (P < 0.001) higher than that in healthy controls (n = 45). C The ROC curve analysis on plasma AS-tDR-007333 level for discriminating NSCLC patients from healthy controls (AUC = 0.9379, sensitivity = 97.78%, specificity = 79.31%). D The expression levels of AS-tDR-007333 in NSCLC cells were higher than that in normal bronchial epithelial cells (BEAS-2B). E qPCR assay revealed that AS-tDR-007333 expression was increased significantly in NSCLC tumor tissues, compared with the corresponding adjacent tissues. F, H FISH assay demonstrated that AS-tDR-007333 expression level was higher in NSCLC tumor tissues (n = 90) than that in the adjacent tissues (n = 86) and increased as NSCLC progressed to more advanced stages. The purple staining represented positive signal. G FISH analysis showed that AS-tDR-007333 was mainly enriched in the cytoplasm. I Higher AS-tDR-007333 levels were associated with shorter overall survival in NSCLC patients (log-rank P value = 0.008; cutoff value: score = 3.0). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001